胎儿大脑护理:胎儿生长受限的大脑神经发育疗法
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
研究概览
详细说明
Randomized controlled trial among pregnant women that have been diagnosed of fetal growth restriction. These women will be randomized in order to evaluate the impact of maternal supplementation with Lactoferrin and DHA on the neurodevelopment outcome of their babies.
Main hypothesis: a prenatal intervention based on maternal supplementation with Lactoferrin and DHA improves neurodevelopment in fetal growth restriction.
Secondary hypothesis are that a prenatal intervention based on maternal supplementation with Lactoferrin and DHA in fetal growth restriction improves fetal growth and improves perinatal morbidity and mortality.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Elisenda Eixarch, MD; PhD
- 电话号码:0034 932279333
- 邮箱:eixarch@clinic.cat
研究联系人备份
- 姓名:Elena Monterde, MD
- 电话号码:0034 932279333
- 邮箱:monterde@clinic.cat
学习地点
-
-
-
Barcelona、西班牙
- 招聘中
- Hospital Dexeus-Quirón
-
接触:
- Gerard Albaigés
-
Barcelona、西班牙
- 招聘中
- Hospital Clínic de Barcelona
-
接触:
- Elisenda Eixarch
- 邮箱:eixarch@clinic.cat
-
副研究员:
- Elena Monterde
-
Barcelona、西班牙
- 招聘中
- Hospital del Mar
-
接触:
- Elena Ferriols
-
Barcelona、西班牙
- 招聘中
- Hospital de la Santa Creu i Sant Pau
-
接触:
- Pablo García-Manau
-
Esplugues de Llobregat、西班牙
- 招聘中
- Hospital Sant Joan de Déu
-
接触:
- Míriam Illa
- 邮箱:milla@sjdhospitalbarcelona.org
-
L'Hospitalet de Llobregat、西班牙
- 招聘中
- Hospital General del Hospitalet
-
接触:
- Susana Fernández
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Singleton pregnancies
- Non-malformed fetus
- Pregnancies with fetal growth restriction
- 24-32.6 weeks of gestation
Exclusion Criteria:
- Chromosomal or structural abnormalities diagnosed during pregnancy or in the neonatal period
- Critical Doppler study suggesting the need for delivery within the next 14 days at the time of diagnosis: reverse end-diastolic velocity in the umbilical artery or ductus venosus pulsatility >95th centile
- Maternal mental or psychiatric disorders
- Maternal allergy to cow's milk protein
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Maternal supplementation with Lactoferrin and DHA
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily |
The intervention consists in the maternal oral administration of 1000mg of Lactoferrin and 1000mg of DHA daily |
|
安慰剂比较:Placebo
Product with the same physical appearance and taste as the main intervention but without therapeutic effect |
Product with the same physical appearance and taste as the main intervention but without therapeutic effect |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Bayley III scale at 24 months of age
大体时间:24 months of corrected postnatal age
|
Bayley III scale is and individually administered instrument that assesses infant development across five domains, including cognitive, language and motor competencies. Parent reported questionnaires are incorporated to assess social-emotional and adaptative behaviors. |
24 months of corrected postnatal age
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cortical development
大体时间:34 weeks of gestation
|
Assessed by fetal brain magnetic resonance imaging. |
34 weeks of gestation
|
|
Fetal brain volume
大体时间:34 weeks of gestation
|
Assessed by fetal brain magnetic resonance imaging. |
34 weeks of gestation
|
|
Corpus callosum area
大体时间:Enrolment, 32 and 36 weeks of gestation
|
Assessed by fetal neurosonography. |
Enrolment, 32 and 36 weeks of gestation
|
|
Neonatal weight
大体时间:Delivery
|
Birth weight |
Delivery
|
|
Perinatal morbidity and mortality
大体时间:Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)
|
Development of one of the following conditions: pregnancy complications, perinatal mortality, metabolic acidosis and major neonatal morbidity. |
Perinatal period: period ranging from 32 weeks of gestation (154 days) to the end of the first 4 weeks of neonatal life (28 days)
|
|
Postnatal neurodevelopmental assessment
大体时间:Between 4 and 24 months of corrected postnatal age
|
Neurodevelopmental assessment using the Bayley III scale at 6 and 24 months of corrected postnatal age, as described in the primary outcome. A complementary neurodevelopmental assessment will be carried out in collaboration with the Speech Acquisition and Perception Groups of the University Pompeu Fabra Barcelona. |
Between 4 and 24 months of corrected postnatal age
|
|
Occurrence of adverse effects
大体时间:Through intervention (supplementation) completion, from enrolment to delivery
|
Record of side effects that may appear. Since intervention is usually well tolerated, we do not expect major side effects. |
Through intervention (supplementation) completion, from enrolment to delivery
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- Fetal Brain Care
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.